CD19 and acute lymphoblastic leukemia: In a separate study, Zhao et al., demonstrated the superiority of humanized selective CAR (hs CAR) in r/r B-ALL patients whose disease progressed after receiving murine anti-CD19 CAR-T cells (ChiCTR1800014761 and ChiCTR1800017439).